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Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG
Antibody, in Systemic Lupus Erythematosus Patients With
Associated Sj€ogren’s Syndrome
Post Hoc Analyses From the EMBODY Trials
Jacques-Eric Gottenberg,1 Thomas D€orner,2 Hendrika Bootsma,3 Valerie Devauchelle-Pensec,4
Simon J. Bowman,5 Xavier Mariette,6 Holger Bartz,7 Marga Oortgiesen,8 Anthony Shock,9
Willem Koetse,8 Catrinel Galateanu,10 Sabine Bongardt,7WilliamA.Wegener,11
DavidM.Goldenberg,11GuyMeno-Tetang,9GordanaKosutic,8 andCarolineGordon12
Objective. EMBODY 1 (ClinicalTrials.gov identi-
fier: NCT01262365) and EMBODY 2 (ClinicalTrials.gov
identifier: NCT01261793) investigated the efficacy and
safety of epratuzumab, a CD22-targeted humanized mono-
clonal IgG antibody, in patients with systemic lupus
erythematosus (SLE). The studies showed no significant
difference from placebo in primary or secondary clinical
outcome measures but did demonstrate B cell–specific
immunologic activity. The aim of this post hoc analysis was
to determine whether epratuzumab had a different clinical
efficacy profile in SLE patients with versus those without
an associated diagnosis of Sjögren’s syndrome (SS).
Methods. The efficacy and safety of epratuzumab
were compared between 2 patient subpopulations random-
ized in EMBODY 1 and 2: SLE patients with and those
without a diagnosis of associated SS. British Isles Lupus
Assessment Group (BILAG) total score, BILAG-based
Combined Lupus Assessment (BICLA) clinical response to
treatment, biologic markers (including B cells, IgG, IgM,
and IgA), and safety were assessed.
Results. A total of 1,584 patients were randomized
in the EMBODY 1 and EMBODY 2 trials; 113 patients
were anti-SSA positive and had a diagnosis of associated
SS, and 1,375 patients (86.8%) had no diagnosis of associ-
ated SS (918 patients were randomized to receive epratu-
zumab and 457 to receive placebo). For patients with
associated SS, but not those without associated SS, a
higher proportion of patients receiving epratuzumab
achieved a BICLA response and a reduction from baseline
in BILAG total score. B cell reduction was faster in
patients with associated SS. The sensitivity of B cells to
epratuzumab as measured by the mean concentration
producing 50% of the maximum B cell count depletion
ClinicalTrials.gov identifiers: NCT01262365; NCT01261793.
Supported by UCB Pharma.
1Jacques-Eric Gottenberg, MD, PhD: Centre de Reference
National pour les Maladies Auto-Immunes Systemiques Rares, CNRS,
Institut de Biologie Moleculaire et Cellulaire, Immunopathologie et Chimie
Therapeutique/Laboratory of Excellence MEDALIS, Strasbourg University
Hospital, Strasbourg, France; 2Thomas D€orner, MD: Charite University
Hospital Berlin, Berlin, Germany; 3Hendrika Bootsma, MD, PhD: Univer-
sity of Groningen, Groningen, The Netherlands; 4Valerie Devauchelle-Pen-
sec, MD, PhD: INSERM 1227, Brest University Medical School, Brest,
France; 5Simon J. Bowman, PhD, FRCP: University Hospitals Birmingham
NHS Foundation Trust, Birmingham, UK; 6Xavier Mariette, MD, PhD:
Universite Paris-Sud, AP-HP, Ho^pitaux Universitaires Paris-Sud, INSERM
U1184, Le Kremlin-Bice^tre, France; 7Holger Bartz, MD, Sabine Bongardt,
MSc: UCB Pharma, Monheim, Germany; 8Marga Oortgiesen, PhD,
Willem Koetse, MS, Gordana Kosutic, MD: UCB, Raleigh, North Caro-
lina; 9Anthony Shock, PhD, Guy Meno-Tetang, PhD: UCB, Slough, UK;
10Catrinel Galateanu, MD: UCB Pharma, Brussels, Belgium; 11William A.
Wegener, MD, PhD, David M. Goldenberg, MD, ScD: Immunomedics,
Morris Plains, New Jersey; 12Caroline Gordon, MD, FRCP: University of
Birmingham and NIHR/Wellcome Trust Clinical Research Facility, Univer-
sity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Dr. D€orner has received research support from UCB Pharma.
Dr. Mariette has received consulting fees from Biogen, Bristol-Myers
Squibb, GlaxoSmithKline, LFB, Pfizer, and UCB Pharma (less than
$10,000 each) and research support from Biogen, Pfizer, and UCB
Pharma. Mr. Koetse and Dr. Kosutic own stock or stock options in UCB
Pharma. Dr. Gordon has received consulting fees, speaking fees, and/or
honoraria from GlaxoSmithKline, MedImmune, Merck Serono, Parexel,
and UCB Pharma (less than $10,000 each).
Address correspondence to Jacques-Eric Gottenberg, MD,
PhD, Department of Rheumatology, Centre de Reference National
pour les Maladies Auto-Immunes Systemiques Rares, CNRS, Institut
de Biologie Moleculaire et Cellulaire, Immunopathologie et Chimie
Therapeutique/Laboratory of Excellence MEDALIS, Strasbourg Uni-
versity Hospital, Avenue Moliere, 6700 Strasbourg, France. E-mail:
jacques-eric.gottenberg@chru-strasbourg.fr.
Submitted for publication June 12, 2017; accepted in revised
form January 23, 2018.
763
ARTHRITIS & RHEUMATOLOGY
Vol. 70, No. 5, May 2018, pp 763–773
DOI 10.1002/art.40425
© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc.
on behalf of American College of Rheumatology. This is an open access article under
the terms of the Creative Commons Attribution-NonCommercial License, which
permits use, distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
was lower for patients with associated SS (9.5 lg/ml) ver-
sus the total EMBODY population (87.1 lg/ml). No differ-
ence in the frequency of adverse events in those receiving
placebo was reported.
Conclusion. Patients with SLE and associated SS
treated with epratuzumab showed improvement in SLE
disease activity, which was associated with bioactivity,
such as decreases in B cell number and IgM level.
Sj€ogren’s syndrome (SS) is a progressive autoim-
mune disease that primarily affects the exocrine glands,
with systemic complications. The disease is characterized
by reduced mucosal secretions resulting in dryness of
mucosal surfaces, which typically manifests as dryness of
the eyes and mouth (1). Histopathologic analyses of
affected tissue samples reveal lymphocyte infiltration, the
formation of ectopic germinal centers, and cell death.
Analyses of the lymphocytes implicate a central role of
B cells in the pathogenesis of the disease (2–5).
SS is described as either primary or associated. Pri-
mary SS develops independently of any other condition,
while associated SS (also known as secondary SS) is linked
to a coexisting autoimmune disease such as systemic lupus
erythematosus (SLE) (6,7). SLE is a chronic autoimmune
disease predominantly affecting the musculoskeletal,
mucocutaneous, and renal systems. Between 6.5% and
19% of patients with SLE develop associated SS (8). The
pathogenesis of SLE and associated SS is associated with
elevated B cell activation and subsequent tissue infiltra-
tion and destruction (9,10); thus, targeting B cells has
been widely seen as a potential therapeutic option for
both SLE and associated SS (11–13).
Epratuzumab (developed by Immunomedics) is a
humanized monoclonal antibody that targets the B cell–
specific protein CD22, resulting in a reduction in both
B cell activity and the number of B cells in peripheral
blood. CD22 is an inhibitory co-receptor of the B cell
receptor (BCR); following ligation to epratuzumab, CD22
is rapidly internalized and phosphorylated (14,15), leading
to the removal of BCR complexes from the cell surface.
This down-modulates BCR-activated signaling, function-
ally inhibiting B cells; for example, there is reduced prolif-
eration and maturation of B cells and a diminished
production of proinflammatory cytokines (16–18).
In the phase IIb EMBLEM trial (19), patients with
moderate-to-severe SLE treated with epratuzumab demon-
strated clinically relevant improvements in disease activity,
which were maintained during the 3.2-year open-label
extension study (20). Following the EMBLEM trial, 2
phase III, randomized, placebo-controlled, double-blind,
multicenter trials (EMBODY 1 and 2) assessed the efficacy
and safety of epratuzumab in the treatment of moderately
to severely active SLE (21). In those trials there was no
statistically significant difference in British Isles Lupus
Assessment Group (BILAG)–based Combined Lupus
Assessment (BICLA) (22) response rates at week 48
between epratuzumab-treated and placebo-treated patients
(the primary end point). Changes in immunologic parame-
ters were observed in epratuzumab-treated patients,
including a 30–40% reduction in the number of peripheral
B cells, consistent with previous studies with epratuzumab.
The efficacy of epratuzumab in primary SS was
evaluated in 2006 in a phase I/II open-label study, in
which 16 patients were enrolled and received 4 infu-
sions of epratuzumab (23). Similar to the EMBLEM
trial in SLE patients, epratuzumab reduced peripheral
B cell counts and was associated with improved clinical
markers of disease activity.
A subset of SLE patients enrolled into the
EMBODY trial were diagnosed as having associated SS
according to their medical history. Since B cells have been
implicated in the pathogenesis of SS, and epratuzumab
has shown efficacy in a small open trial of patients with pri-
mary SS, the objective of this post hoc analysis was to
determine whether epratuzumab demonstrated a different
clinical efficacy profile in SLE patients with a diagnosis of
associated SS.
PATIENTS AND METHODS
The analyses reported here represent post hoc ana-
lyses of the EMBODY trials (ClinicalTrials.gov identifiers:
NCT01262365 and NCT01261793). The EMBODY trial inclu-
sion and exclusion criteria, and the study design, have been
reported previously (21) and are described briefly below.
Patients. To be eligible for inclusion in the EMBODY tri-
als, patients had to be ≥18 years of age and have a diagnosis of
moderately to severely active SLE fulfilling ≥4 of 11 of the revised
American College of Rheumatology criteria (24) (if patients had
a neurologic disorder, ≥5 of 11 criteria were required). All
patients had disease activity in the musculoskeletal, mucocuta-
neous, or cardiorespiratory systems, as defined by the BILAG
Index (2004 version) (25,26). Patients must have had BILAG
grade A activity in ≥1 of these systems, or BILAG grade B activity
in ≥2 of these systems. Additionally, all patients had an SLE Dis-
ease Activity Index 2000 (SLEDAI-2K) (27) score of ≥6, and had
to be positive at screening for antinuclear antibodies (ANAs; titer
≥1:80) and/or anti–double-stranded DNA (defined as a positive
result on either a multiplex immunoassay or a Farr assay). Key
exclusion criteria included SLE disease activity involving the renal
system (defined by BILAG level A renal activity); serum crea-
tinine level of >2.5 mg/dl, a clinically significant increase in serum
creatinine level within 4 weeks prior to screening, or proteinuria
>3.5 gm/day; and severe neuropsychiatric SLE disease.
Study design. EMBODY 1 and EMBODY 2 were identi-
cal phase III, randomized, double-blind, placebo-controlled, mul-
ticenter studies (21). The studies consisted of a 2-week screening
period, followed by a 48-week double-blind treatment period, and
a 4-week safety follow-up (13 weeks for patients who discontinued
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prior to week 48). Patients were randomized 1:1:1 to receive pla-
cebo, epratuzumab 600 mg every week, or epratuzumab 1,200 mg
every other week. Infusions of active drug or placebo were admin-
istered over a 4-week dosing period at the beginning of each 12-
week treatment cycle. This dosing pattern was repeated for 4
cycles (48 weeks total). In all cases, the study drug was given in
addition to the patients’ existing standard therapy, consisting of
corticosteroids, antimalarials, and/or immunosuppressants.
Post hoc analyses. The efficacy and safety of epratuzu-
mab compared to placebo were assessed in 2 subpopulations of
randomized patients. The first subpopulation (patients with
associated SS) consisted of SLE patients with a diagnosis of
associated SS according to their medical history (provided by
patients at screening) who were positive for anti-SSA (also
called anti-Ro). The second subpopulation (patients without
associated SS) consisted of all other SLE patients (i.e., those
without a medical history of associated SS). Two sets of sensitiv-
ity analyses were performed for all outcomes, one on SLE
patients positive for anti-SSA and the other on SLE patients
negative for anti-SSA. Unexpectedly, some patients were posi-
tive for antidrug antibody at baseline before receiving epratuzu-
mab or placebo. Because the significance of baseline antidrug
antibody is uncertain, patients positive for antidrug antibody at
baseline were excluded from all analyses.
The proportion of patients with a BICLA response was
recorded at each study visit. All of the following were required to
achieve a BICLA response: all BILAG As at study entry im-
proved to B, C, or D, all BILAG Bs improved to C or D, no new
BILAG As, no more than 1 new BILAG B, no worsening (no
increase) in SLEDAI-2K total score compared to study entry, no
worsening in physician’s global assessment of disease activity
(PGA) compared to study entry (<10-mm increase on a 100-mm
visual analog scale [VAS]), and no disallowed changes in concomi-
tant medications, including increase in or addition of immunosup-
pressants or antimalarials compared to baseline, increase of
>25% in corticosteroids compared to baseline from week 0 to 8,
or any increase in corticosteroids compared to baseline after week
8 for an SLE-related indication. Other clinical efficacy variables
included BILAG total score (generated by converting A, B, C, D,
and E to 12, 8, 1, 0, and 0, respectively [28]), PGA (on a 100-mm
VAS), and SLEDAI total score at each visit. Pharmacodynamic
(PD) and immunologic variables included levels of CD19+ B cells,
immunoglobulins, autoantibodies, extractable nuclear antigen
antibodies, and complement proteins. Measurements of immuno-
logic and lupus-associated laboratory parameters, including anti-
SSA autoantibodies, were conducted by a central laboratory.
The pharmacokinetics (PK) of epratuzumab were char-
acterized using nonlinear mixed-effects modeling (population
approach). The following epratuzumab exposure measurements
were determined: the average plasma concentration at steady
state (Cssav) for each 12-week treatment period, and the pre-
dicted plasma concentration at each study visit (Cvisit). Cssav was
derived from patient-specific estimates of epratuzumab clearance
(CL; liter/week) and the total dose over the 12-week treatment
period (i.e., 2,400 mg; dose 12w) using the following equation:
Cssav ¼ Dose12wðCL  12Þ
Cvisit was the patient-specific prediction of epratuzumab plasma
concentration at the time of each study visit based on the
established population PK model.
The total B cell count was modeled as a continuous PD
variable that was allowed to change from baseline over the study
duration for each individual. The effect of epratuzumab exposure
on the B cell count, corrected for placebo effects, was described
using an Emax model, where the effect increases in a nonlinear
manner to a maximum value (Emax). The model comprised 2
parameters: the concentration of epratuzumab producing 50% of
the maximum response (EC50), and the maximum effect pro-
duced (Emax). The population PK/PD model for B cell count was
first developed with the complete data set, and then applied to
the associated SS subpopulation to assess placebo and epratuzu-
mab exposure-response for each population.
Treatment-emergent adverse events (AEs) and serious
treatment-emergent AEs were monitored throughout the study.
Statistical analysis. Efficacy variables were analyzed
using the full analysis set, which consisted of all patients with a
valid baseline and post-baseline measurement who received at
least one partial dose of study medication. For BICLA response,
missing data were imputed using modified nonresponder impu-
tation, with P values calculated using logistic regression with fac-
tors for treatment, pooled region, and baseline disease severity.
For change from baseline in total BILAG score, PGA,
and total SLEDAI score, missing values were imputed using last
observation carried forward, and P values were calculated (at
weeks 24 and 48 only) using analysis of covariance adjusted for
baseline, pooled region, and baseline disease severity. Observed
values were used for all immunologic and serologic measure-
ments. Safety variables for this analysis were analyzed using the
full analysis set.
RESULTS
Patient disposition and baseline characteristics.
A total of 1,584 patients were randomized in EMBODY
1 and EMBODY 2 (21). Of these, 113 patients were
anti-SSA positive and had a diagnosis of associated SS
(7.1%; 73 patients were randomized to the epratuzumab
group and 40 to placebo; 33 patients [29.5%] were diag-
nosed as having SS before their SLE diagnosis); 1,375
patients (86.8%) had no diagnosis of associated SS (918
patients were randomized to the epratuzumab group and
457 to placebo).
Of all the patients randomized to the EMBODY 1
and 2 trials, 96 (6.1%) were excluded from the analysis
because they did not meet the subset definitions or were
positive for antidrug antibody at baseline. These patients
were either antidrug antibody positive at baseline (48
patients), had a diagnosis of associated SS but were not
anti-SSA positive (39 patients), or were both antidrug anti-
body positive at baseline and had a diagnosis of associated
SS but were not anti-SSA positive (9 patients). In total,
1,329 patients without associated SS and 112 patients with
associated SS received at least 1 dose of study drug and
had a post-baseline assessment and were included in the
full analysis set.
Overall, 26 patients with associated SS (35.6%)
and 298 patients without associated SS (32.5%) receiving
EFFICACY OF EPRATUZUMAB IN SLE-ASSOCIATED SS 765
epratuzumab, and 16 patients with associated SS (40.0%)
and 150 patients without associated SS (32.8%) receiving
placebo discontinued before the end of the study (data
are available upon request from the corresponding
author). The most common reasons for discontinuation
were AEs and lack of efficacy. Patient characteristics,
patient clinical features, and the proportion of patients
receiving controlled medications at baseline were similar
for both patients with associated SS and patients without
associated SS (Table 1), although small differences were
apparent in sex, age, and serologic profiles.
Clinical response. The primary analysis of the
EMBODY trials revealed no significant difference be-
tween the epratuzumab and placebo treatment groups in
BICLA response rate, change from baseline in BILAG
total score, or PGA at week 48 (21).
Consistent with these results, SLE patients without
associated SS receiving epratuzumab failed to demonstrate
a BICLA response compared with placebo for the primary
end point at week 24. Differences in BICLA response com-
pared with placebo were only observed at weeks 12, 16, and
20 for patients receiving 600 mg every week, and no differ-
ence was observed at any time point for patients receiving
1,200 mg every other week (Figure 1A). In contrast, a rapid
BICLA response was observed for SLE patients with associ-
ated SS who were anti-SSA positive. By week 16, BICLA
response was greater in patients receiving epratuzumab
than in those receiving placebo (P < 0.05). This response
was maintained through week 48 (Figure 1E).
Similar to the BICLA response rate, only a small
difference was observed in change in total BILAG score
from baseline in patients without associated SS receiving
Table 1. Baseline demographic and disease characteristics of patients with SLE with and those without associated SS*
Non-SS patients SS patients†
Placebo
(n = 443)
Epratuzumab
600 mg
(n = 450)
Epratuzumab
1,200 mg
(n = 436)
Placebo
(n = 40)
Epratuzumab
600 mg
(n = 31)
Epratuzumab
1,200 mg
(n = 41)
Age, mean  SD years 40.7  12.4 41.4  12.0 41.0  11.5 44.3  11.9 46.4  12.3 47.2  11.0
Sex, no. (%) female 414 (93.5) 412 (91.6) 406 (93.1) 40 (100) 30 (96.8) 41 (100)
Weight, mean  SD kg 72.3  19.9 71.6  18.7 73.2  19.5 68.2  16.7 72.2  26.6 69.1  15.3
BMI, mean  SD kg/m2 27.1  7.3 26.7  6.9 27.2  7.0 25.5  6.0 26.8  8.8 25.9  5.0
Time since SS diagnosis, median
(range) years
– – – 7.5 (0–2.6) 5.1 (0–34) 5.3 (0–32)
Time since SLE diagnosis, median
(range) years
5.7 (0–37) 5.5 (0–43) 6.0 (0–34) 7.3 (0–33) 7.7 (0–40) 6.7 (0–29)
SLEDAI total score, median
(range)
10 (4–28) 10 (4–25) 10 (4–27) 10 (4–22) 10 (4–22) 9 (6–21)
Physician’s global assessment of disease activity,
median (range)
55 (15–87) 57 (12–100) 56 (13–92) 54 (15–79) 58 (25–99) 58 (27–91)
Patient’s global assessment of disease activity,
median (range)
60 (3–100) 62 (5–100) 62 (0–100) 60 (5–83) 56 (3–86) 59 (0–95)
BILAG total score, median
(range)‡
20 (2–60) 19.5 (9–45) 20 (9–60) 20 (12–37) 20 (13–42) 20 (12–56)
Medication use at baseline, no. (%)
Immunosuppressants 204 (46.0) 208 (46.2) 206 (47.2) 18 (45.0) 18 (58.1) 21 (51.2)
Antimalarials 296 (66.8) 317 (70.4) 294 (67.4) 23 (57.5) 20 (64.5) 25 (61.0)
Antimalarials and immunosuppressants 134 (30.2) 142 (31.6) 140 (32.1) 10 (25.0) 11 (35.5) 17 (41.5)
Corticosteroids 411 (92.8) 434 (96.4) 417 (95.6) 35 (87.5) 29 (93.5) 37 (90.2)
ANA titer >1:80, no. (%) 382 (86.2) 395 (87.8) 382 (87.6) 40 (100) 29 (93.5) 39 (95.1)
Anti-dsDNA positive, no. (%) 245 (55.3) 229 (50.9) 226 (51.8) 21 (52.5) 20 (64.5) 12 (29.3)
Low complement, no. (%)§ 207 (46.7) 212 (47.1) 196 (45.0) 24 (60.0) 14 (45.2) 19 (46.3)
Anti-Sm positive, no. (%) 115 (26.1) 107 (23.9) 119 (27.5) 12 (30.0) 10 (32.3) 6 (14.6)
Anti-RNP positive, no. (%) 123 (28.0) 129 (28.9) 133 (30.7) 13 (32.5) 11 (35.5) 8 (19.5)
Anti-SSA positive, no. (%)¶ 200 (45.5) 198 (44.3) 203 (46.9) 40 (100) 31 (100) 41 (100)
Anti-SSB positive, no. (%) 78 (17.7) 86 (19.2) 77 (17.8) 23 (57.5) 19 (61.3) 22 (53.7)
CRP, mean  SD mg/liter 8.6  12.9 8.0  10.6 8.4  15.7 3.9  4.0 8.5  13.2 5.5  6.7
* Analyses were conducted using the full analysis set. Data were not available for all patients. Epratuzumab 600 mg was administered weekly,
and epratuzumab 1,200 mg was administered every other week. Both dosing regimens were repeated for 4 weeks every 12 weeks. BMI = body
mass index; SLEDAI = Systemic Lupus Erythematosus Disease Activity Index; BILAG = British Isles Lupus Assessment Group; ANA = anti-
nuclear antibody; anti-dsDNA = anti–double-stranded DNA; CRP = C-reactive protein.
† Systemic lupus erythematosus (SLE) patients with a diagnosis of Sj€ogren’s syndrome (SS) according to their medical history who were also
anti-SSA positive.
‡ Generated by converting A, B, C, D, and E to 12, 8, 1, 0, and 0, respectively.
§ Defined as a C3 level of <0.9 gm/liter or a C4 level of <180 mg/liter.
¶ Defined according to the rules of the central laboratory, which may have varied across treatment regions.
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epratuzumab versus those receiving placebo (Figure 1B).
However, differences were observed in SLE patients with
associated SS. By week 24, patients receiving either epra-
tuzumab dosing regimen reported greater reductions in
total BILAG score compared with placebo (P < 0.05) (Fig-
ure 1F). No significant differences, but a trend in favor of
epratuzumab response, were observed for both PGA
response rate and SLEDAI change from baseline in both
SLE patients without associated SS and those with associ-
ated SS receiving epratuzumab versus placebo (Fig-
ures 1C, D, G, and H).
At baseline, serum C-reactive protein (CRP) con-
centration was higher in the patients without associated SS
(Table 1). To assess whether baseline CRP levels had an
effect on the clinical efficacy measurements, the total
EMBODY population was reanalyzed according to CRP
levels at baseline, using the median value (3.0 mg/liter
[range 0.12–182.09]) as a cutoff (data available upon
request from the corresponding author). Compared to
placebo, changes from baseline in total BILAG score,
BICLA response, PGA, and SLEDAI were greater for
patients with a CRP concentration higher than the median
value.
Immunologic response. By week 48 in the
EMBODY trials, a reduction in B cell count from baseline
of between 30% and 40% was observed in SLE patients
receiving epratuzumab. Consistent with these results, a
reduction in CD19+ B cell count of between 30% and 40%
was observed in both patients without associated SS and
patients with associated SS receiving epratuzumab, but not
those receiving placebo (Figures 2A and B). No difference
was seen between patients with associated SS and those
without associated SS.
PK/PD modeling was used to compare the effect
of the serum epratuzumab concentration on CD19+ B
cell count at week 48 (Figure 2C). B cell counts were
reduced by ~30% of baseline values in both the entire
SLE population and the patients with associated SS.
Figure 1. A–D, British Isles Lupus Assessment Group (BILAG)–based Combined Lupus Assessment (BICLA) response rate (A), change in total
BILAG score from baseline (B), change in physician’s global assessment (PGA) from baseline (C), and change in Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) from baseline (D) in SLE patients without associated Sj€ogren’s syndrome (SS; non-aSjS patients) receiving pla-
cebo or epratuzumab (Emab). E–H, BICLA response rate (E), change in total BILAG score from baseline (F), change in PGA from baseline (G),
and change in SLEDAI from baseline (H) in SLE patients with associated SS receiving placebo or epratuzumab. Analyses were conducted using
the full analysis set. Values are the median percent change from baseline. For total BILAG score, PGA, and SLEDAI, statistical testing was con-
ducted only at weeks 24 and 48. Nonresponder imputation was used for the BICLA response. The last observation carried forward method was
used to impute missing values for the total BILAG score, PGA, and SLEDAI. Light asterisk = P < 0.05 for epratuzumab 1,200 mg every other
week (QOW) versus placebo; dark asterisk = P < 0.05 for epratuzumab 600 mg every week (QW) versus placebo.
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However, the reduction was faster in the population
with associated SS, and the sensitivity to epratuzumab,
as measured by the EC50, was substantially lower for
patients with associated SS receiving epratuzumab
(9.5 lg/ml) compared with the total EMBODY popula-
tion (87.1 lg/ml).
Reductions in IgM levels were greater in patients
receiving epratuzumab compared with those receiving
placebo and were similar for patients with and those with-
out associated SS (Figure 3). By week 48 in both groups,
median percentage changes from baseline of ~20% were
observed for patients receiving epratuzumab compared
with no change in patients receiving placebo (Figures 3A
and C). No changes in either IgG (Figures 3B and D) or
IgA (data not shown) were observed over the 48 weeks in
any group.
Serum concentration of anti-SSA decreased from
baseline through week 48 in patients with associated SS and
was greater in patients receiving either dose of epratuzumab
(51.24 units/ml and 84.45 units/ml) versus placebo
(26.83 units/ml). However, no changes were observed in
patients without associated SS (Figures 4A and C) (data
are available upon request from the corresponding author).
No significant differences in anti-SSB titers between treat-
ment groups were observed for either population (Fig-
ures 4B and D).
Subgroup analyses. To discern whether anti-SSA
positivity contributed to the clinical responses observed
above, all analyses performed for this study were repeated
for anti-SSA–positive patients without associated SS and
anti-SSA–negative patients without associated SS. At
baseline, demographic and disease characteristics were
similar between the groups (data are available upon
request from the corresponding author).
Changes from baseline in total BILAG score,
PGA, SLEDAI, CD19+ cell count, IgM, IgG, and anti-
SSB at each study visit were similar for both patient popu-
lations and consistent with the results reported above
(data are available upon request from the corresponding
author). Differences between the 2 patient populations
were only observed for BICLA response rate, where there
was a greater difference between the epratuzumab and
the placebo arms for anti-SSA–positive patients without
associated SS than anti-SSA–negative patients without
associated SS. However, the magnitude of the difference
between the treatment and placebo arms was similar to
the difference observed in the original population of
patients without associated SS.
Safety. In this subpopulation of SLE patients with a
diagnosis of associated SS, the incidence of AEs was com-
parable between the placebo and epratuzumab treatment
groups, and was similar to the incidence of treatment-
Figure 2. A and B, Percentage change from baseline in CD19+ cells
from patients with systemic lupus erythematosus (SLE) without asso-
ciated Sj€ogren’s syndrome (SS; non-aSjS patients) (A) and patients
with SLE with associated SS (B) receiving placebo or epratuzumab
(Emab). C, Pharmacokinetics/pharmacodynamics modeling of B cell
reduction following intravenous epratuzumab. Dotted lines represent
the 5th, 25th, 75th, and 95th percentiles, respectively, of the observed
epratuzumab average steady-state plasma drug concentration during
multiple-dose administration; broken line represents the 50th percen-
tile. The shaded area shows the 95% confidence interval based on
500 bootstrap sampling with replacement available for all the “All
data” model only. QOW = every other week; QW = every week.
Color figure can be viewed in the online issue, which is available at
http://onlinelibrary.wiley.com/doi/10.1002/art.40425/abstract.
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emergent AEs reported by non-SS patients (Table 2). Treat-
ment-emergent AEs occurred in 61 patients receiving
epratuzumab (84.7%) and 33 patients receiving placebo
(82.5%). Serious AEs occurred in 15 patients receiving epra-
tuzumab (20.8%) and 7 patients receiving placebo (17.5%).
There was 1 death in the associated SS subpopulation; this
was in the placebo treatment group, and therefore unrelated
to the study drug. The death was caused by pneumonia.
DISCUSSION
In this post hoc analysis of the EMBODY phase
III trials, treatment with epratuzumab in addition to stan-
dard therapies resulted in improved SLE-specific clinical
outcomes at week 48 compared with placebo in patients
with a diagnosis of associated SS. Similar to the published
EMBODY results (21), no improvements in SLE-specific
clinical outcomes at week 48 were observed in patients
without a diagnosis of associated SS.
The mechanism of action driving the different
responses in the 2 study populations is not known. How-
ever, since epratuzumab reduces B cell activity and the
number of B cells in peripheral blood targets, differences
in B cell response to epratuzumab may lead to different
SLE-specific clinical outcomes at week 48. To investigate
this, changes in B cell numbers and immunoglobulin (IgM,
IgG, and IgA) concentrations were compared. Interest-
ingly, despite the different responses observed in SLE-
Figure 3. A and B, Median percent change from baseline in IgM (A) and IgG (B) serum concentrations in patients with systemic lupus erythematosus
(SLE) without associated Sj€ogren’s syndrome (SS; non-aSjS) receiving placebo or epratuzumab (Emab). C and D, Median percent change from base-
line in IgM (C) and IgG (D) serum concentrations in patients with SLE with associated SS receiving placebo or epratuzumab. Analyses were conducted
using the full analysis set and observed data. Values are the median (25th–75th percentile) percent change from baseline. QOW = every other week;
QW= every week. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40425/abstract.
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Figure 4. A and B, Mean change from baseline in anti-SSA (A) and anti-SSB (B) in patients with systemic lupus erythematosus (SLE) without
associated Sj€ogren’s syndrome (SS; non-aSjS) receiving placebo or epratuzumab (Emab). C and D, Mean change from baseline in anti-SSA (C)
and anti-SSB (D) in patients with SLE with associated SS receiving placebo or epratuzumab. Analyses were conducted using the full analysis set
and observed data. Values are the mean (95% confidence interval) change from baseline. QOW = every other week; QW = every week. Color fig-
ure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40425/abstract.
Table 2. Summary of treatment-emergent AEs*
Non-SS patients SS patients
Placebo
(n = 443)
Epratuzumab
600 mg
(n = 450)
Epratuzumab
1,200 mg
(n = 436)
Placebo
(n = 40)
Epratuzumab
600 mg
(n = 31)
Epratuzumab
1,200 mg
(n = 41)
Any treatment-emergent AE 374 (84.4) 374 (83.1) 377 (86.5) 33 (82.5) 28 (90.3) 33 (80.5)
Serious treatment-emergent AEs 75 (16.9) 77 (17.1) 75 (17.2) 7 (17.5) 7 (22.6) 8 (19.5)
Discontinuation due to treatment-emergent AEs 33 (7.4) 22 (4.9) 35 (8.0) 3 (7.5) 4 (12.9) 1 (2.4)
Infusion reaction treatment-emergent AEs 32 (7.2) 31 (6.9) 49 (11.2) 2 (5.0) 4 (12.9) 5 (12.2)
Drug-related treatment-emergent AEs 126 (28.4) 131 (29.1) 152 (34.9) 13 (32.5) 9 (29.0) 13 (31.7)
Severe treatment-emergent AEs 63 (14.2) 62 (13.8) 61 (14.0) 5 (12.5) 5 (16.1) 8 (19.5)
All deaths 3 (0.7) 1 (0.2) 3 (0.7) 1 (2.5) 0 (0.0) 0 (0.0)
* Analyses were conducted using the full analysis set. Values are the number (%). AEs = adverse events; SS = Sj€ogren’s syndrome.
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specific clinical outcomes, no differences were observed in
changes from baseline in either immunoglobulin concen-
tration or B cell count. Exposure-response analysis for B
cell reduction modeling over placebo was used to further
compare the effect of epratuzumab on B cells in the 2
patient populations. Differences were observed that sug-
gested that B cells from patients with associated SS
respond more quickly to epratuzumab than B cells from
patients without associated SS.
The majority of the baseline demographics of the
patients with associated SS were similar to those of the
wider SLE population enrolled in the trial. However,
there were differences. Mean patient age and the propor-
tion of women were both higher in the group with associ-
ated SS. Serologic differences were also observed; CRP
was lower and anti-SSB was higher in the associated SS
population, while anti-ANA and anti-Sm were lower.
Analyses investigating whether CRP level correlates with
treatment outcomes were performed by grouping patients
according to high and low CRP levels using the median
value as a cutoff. These analyses suggested that the effi-
cacy of epratuzumab may be higher in patients with high
CRP levels at baseline in the original study. However,
although baseline CRP values were higher in the patients
without associated SS than in the patients with associated
SS, measures of epratuzumab efficacy were lower in these
patients without SS. These results suggest that CRP does
not represent a helpful biomarker in identifying patients
who may respond to epratuzumab.
There is published evidence of differences in
impaired B cell regulation in Sj€ogren’s patients compared
with SLE patients which may contribute to the clinical
response achieved by patients with associated SS.
Although SLE and associated SS are both characterized
by hyperactivated B cells, in SS, exocrine glands are the
primary target for the disease, which is thought to be
mediated by an antigen-driven, germinal center–type
B cell response (29,30). Taken together, these data sug-
gest that the pathophysiology of associated SS may differ
from that in the wider SLE population. If these differ-
ences provide a better target for epratuzumab, this may
explain why clinical efficacy and the exposure-response
analysis for B cell reduction modeling over placebo were
only observed in patients with associated SS, despite simi-
lar B cell reductions being observed in both populations.
To date, no clinical trials have prospectively
assessed the efficacy of B cell modulators in patients with
SLE and an associated diagnosis of SS. The few trials that
have investigated B cell modulators as a potential therapy
for SS have assessed their use in patients with primary SS.
The efficacy of rituximab, an anti-CD20 mono-
clonal antibody, in patients with primary SS has been
assessed in several trials. In 2 phase II trials, rituximab
reduced the signs and symptoms of the disease, improv-
ing salivary production, health-related quality of life, and
measures of fatigue (31,32). Similar results were
observed in the Tolerance and Efficacy of Rituximab in
Primary Sj€ogren’s Syndrome (TEARS) trial (33). This
trial enrolled 120 patients with primary SS. Although it
failed its primary end point, the trial demonstrated early
clinical improvements and improvements in patient-
reported outcomes. The Trial of Anti–B Cell Therapy in
Patients with Primary Sj€ogren’s Syndrome (TRACTISS),
a multicenter, randomized, double-blind, parallel-group
placebo-controlled trial, was designed to further assess
the potential benefits of rituximab in SS patients (34).
This study also failed to meet its clinical end point; the
only outcome measure with a significant improvement
was unstimulated saliva flow. This might be related to
the incomplete depletion of salivary autoreactive B cells,
the absence of targeting of pathogenic long-lived plasma
cells, and the effect of rituximab on regulatory (protec-
tive) B cells.
The Belimumab in Sj€ogren’s Syndrome (BELISS)
study was an open-label trial assessing the efficacy and
safety of belimumab, an anti–B lymphocyte stimulator
monoclonal antibody, in primary SS. The trial enrolled 30
patients and achieved its week 28 primary end point of
improvement in 2 of 5 items: reduction of ≥30% in dryness
score on a VAS, ≥30% in fatigue VAS score, ≥30% in VAS
pain score, ≥30% in systemic activity VAS assessed by the
physician and/or >25% improvement in any B cell activa-
tion biomarker values (35). Based on these criteria, 60% of
patients receiving belimumab achieved a clinical response.
Similar effects were observed in the only open trial
to date assessing the efficacy of epratuzumab in primary
SS, although caution is required when interpreting the
results because that study included only 16 patients (23).
A reduction of <30% in total B cell count was maintained
throughout the 32-week trial, and 53% of the patients
achieved at least a 20% improvement in 2 of the following
4 domains: dryness of the eyes (Schirmer I test), dryness of
the mouth, fatigue (VAS), and erythrocyte sedimentation
rate and/or IgG level. The results of that study, in
conjunction with the results from the BELISS and
TEARS trials, suggest that anti–B cell therapies may
be effective in the treatment of associated SS or SLE
patients with anti-SSA antibodies.
There were several limitations to this study. The
EMBODY program was designed to assess the clinical
efficacy and safety of epratuzumab in SLE patients, and so
no associated SS–specific clinical data were collected.
Patients with associated SS were identified from a clini-
cian’s identification and diagnosis of the disease, and so
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may not be accurate (since no formal objective assessment
of tear, salivary flow, or salivary gland biopsy was per-
formed or assessed according to the American-European
Consensus Group proposed definition for associated SS
[36]). Consequently, patients may have been incorrectly
categorized as not having associated SS. This could explain
why BICLA response was higher in anti-SSA–positive
patients without associated SS, since some patients might
have been diagnosed as having associated SS if they had
been fully assessed; however, the additional selection crite-
rion of a positive anti-SSA titer was included for a more
defined SS patient population. The population size
assessed, although relatively large for a Sj€ogren’s study,
included only 112 patients in the full analysis set. The effi-
cacy and safety of epratuzumab in a larger patient popula-
tion with SS-specific outcome measures now needs to be
assessed to determine if epratuzumab would be helpful for
treating patients with SS. In addition, other studies could
be considered to determine whether lupus patients with
anti-SSA (and/or anti-SSB) antibodies are more likely to
respond to epratuzumab and other B cell–targeted thera-
pies than those with other serologic phenotypes.
In conclusion, patients with SLE and associated SS
treated with epratuzumab showed improvements in SLE
disease activity compared with patients treated with pla-
cebo, which was not observed in patients without associ-
ated SS. B cell numbers, IgM levels, and anti-SSA levels
were consistently reduced in all patient populations receiv-
ing epratuzumab; however, B cell reduction was faster in
the associated SS patient population. These data suggest
that epratuzumab may have clinical benefits in certain
subsets of SLE patients and so stratification of SLE
patients may be appropriate. Further trials examining
the effectiveness of epratuzumab in primary SS are
needed to confirm the effectiveness of epratuzumab in
this population.
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